Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: Molecular targeting in cholangiocarcinoma

Journal of Surgical Research

Volumn 198, Issue 2, 2015, Pages 434-440

  Koprowski, Steven ^a   Sokolowski, Kevin ^a   Kunnimalaiyaan, Selvi ^a   Clark Gamblin, T ^a   Kunnimalaiyaan, Muthusamy ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Apoptosis; Cholangiocarcinoma; Curcumin; Notch signaling; Survivin

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CASPASE 7; CURCUMIN; CYCLIN D1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH1 RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR HES 1; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BIRC5 PROTEIN, HUMAN; HES1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; NOTCH1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL LYSATE; CELL SURVIVAL; CELL VIABILITY; CHOLANGIOCARCINOMA CELL LINE; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BILE DUCT NEOPLASMS; CELL CYCLE; CHOLANGIOCARCINOMA; CURCUMA; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PHYTOTHERAPY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BILE DUCT NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHOLANGIOCARCINOMA; CURCUMA; CURCUMIN; DRUG SCREENING ASSAYS, ANTITUMOR; HOMEODOMAIN PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PHYTOTHERAPY; RECEPTOR, NOTCH1;

EID: 84940208364     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2015.03.029     Document Type: Review

References (46)

1. B. Blechacz, M. Komuta, T. Roskams, and G.J. Gores Clinical diagnosis and staging of cholangiocarcinoma Nat Rev Gastroenterol Hepatol 8 2011 512
2. M.L. Deoliveira, R.D. Schulick, Y. Nimura, and et al. New staging system and a registry for perihilar cholangiocarcinoma Hepatology 53 2011 1363
3. J.E. Everhart, and C.E. Ruhl Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas Gastroenterology 136 2009 1134
4. S.A. Khan, B.R. Davidson, R.D. Goldin, and et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update Gut 61 2012 1657
5. V. Cardinale, R. Semeraro, A. Torrice, and et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors World J Gastrointest Oncol 2 2010 407
6. M.J. Olnes, and R. Erlich A review and update on cholangiocarcinoma Oncology 66 2004 167
7. T.M. Welzel, K.A. McGlynn, A.W. Hsing, T.R. O'Brien, and R.M. Pfeiffer Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States J Natl Cancer Inst 98 2006 873
8. A.E. Sirica Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy Hepatology 41 2005 5
9. S. Hasegawa, I. Ikai, H. Fujii, E. Hatano, and Y. Shimahara Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications World J Surg 31 2007 1256
10. A. Guglielmi, A. Ruzzenente, F. Bertuzzo, and C. Iacono Assessment of nodal status for perihilar cholangiocarcinoma location, number, or ratio of involved nodes Hepatobiliary Surg Nutr 2 2013 281
11. A. Guglielmi, A. Ruzzenente, T. Campagnaro, and et al. Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma J Gastrointest Surg 17 2013 1917
12. J. Valle, H. Wasan, D.H. Palmer, and et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273
13. S.Y. Park, J.H. Kim, H.J. Yoon, I.S. Lee, H.K. Yoon, and K.P. Kim Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma Clin Radiol 66 2011 322
14. Z.F. Wu, H.B. Zhang, N. Yang, W.C. Zhao, Y. Fu, and G.S. Yang Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series Eur J Surg Oncol 38 2012 602
15. M.C. Cantarini, S.M. de la Monte, M. Pang, and et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms Hepatology 44 2006 446
16. I. Espinoza, and L. Miele Notch inhibitors for cancer treatment Pharmacol Ther 139 2013 95
17. M. Evert, F. Dombrowski, B. Fan, S. Ribback, X. Chen, and D.F. Calvisi On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development Hepatology 58 2013 1857
18. G. Frampton, M. Coufal, H. Li, J. Ramirez, and S. DeMorrow Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling Exp Cell Res 316 2010 1465
19. W.R. Wu, R. Zhang, X.D. Shi, and et al. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro Oncol Rep 31 2014 2515
20. Q. Zhou, Y. Wang, B. Peng, L. Liang, and J. Li The roles of Notch1 expression in the migration of intrahepatic cholangiocarcinoma BMC Cancer 13 2013 244
21. Z. Wang, Y. Zhang, S. Banerjee, Y. Li, and F.H. Sarkar Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells Cancer 106 2006 2503
22. A.B. Kunnumakkara, P. Anand, and B.B. Aggarwal Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins Cancer Lett 269 2008 199
23. M. Metzler, E. Pfeiffer, S.I. Schulz, and J.S. Dempe Curcumin uptake and metabolism Biofactors 39 2013 14
24. S. Pinlaor, P. Yongvanit, S. Prakobwong, and et al. Curcumin reduces oxidative and nitrative DNA damage through balancing of oxidant-antioxidant status in hamsters infected with Opisthorchis viverrini Mol Nutr Food Res 53 2009 1316
25. S. Prakobwong, S.C. Gupta, J.H. Kim, and et al. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways Carcinogenesis 32 2011 1372
26. S. Prakobwong, J. Khoontawad, P. Yongvanit, and et al. Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis Int J Cancer 129 2011 88
27. A. Shehzad, J. Lee, and Y.S. Lee Curcumin in various cancers Biofactors 39 2013 56
28. A. Shehzad, and Y.S. Lee Molecular mechanisms of curcumin action: signal transduction BioFactors 39 2013 27
29. J.C. Tilak, M. Banerjee, H. Mohan, and T.P. Devasagayam Antioxidant availability of turmeric in relation to its medicinal and culinary uses Phytother Res 18 2004 798
30. A. Shehzad, G. Rehman, and Y.S. Lee Curcumin in inflammatory diseases BioFactors 39 2013 69
31. M. El Khatib, P. Bozko, V. Palagani, N.P. Malek, L. Wilkens, and R. Plentz Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo PloS One 8 2013 e77433
32. S. Liao, J. Xia, Z. Chen, and et al. Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-kappaB signaling pathways J Cell Biochem 112 2011 1055
33. D. Subramaniam, S. Ponnurangam, P. Ramamoorthy, and et al. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling PloS One 7 2012 e30590
34. Y.M. Carter, S. Kunnimalaiyaan, H. Chen, T.C. Gamblin, and M. Kunnimalaiyaan Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth Cancer Biol Ther 15 2014 510
35. G. Nuzzo, F. Giuliante, F. Ardito, and et al. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection Updates Surg 62 2010 11
36. G. Ramacciato, G. Nigri, R. Bellagamba, and et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma Am Surg 76 2010 1260
37. T. Sano, K. Shimada, Y. Sakamoto, J. Yamamoto, S. Yamasaki, and T. Kosuge One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality Ann Surg 244 2006 240
38. Y.H. Shaib, J.A. Davila, L. Henderson, K.A. McGlynn, and H.B. El-Serag Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study J Clin Gastroenterol 41 2007 911
39. Y. Chen, D. Li, H. Liu, and et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells Cancer Biol Ther 11 2011 14
40. R.D. Meng, C.C. Shelton, Y.M. Li, and et al. Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity Cancer Res 69 2009 573
41. S. Naganuma, K.A. Whelan, M. Natsuizaka, and et al. Notch receptor inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous cell carcinoma Am J Cancer Res 2 2012 459
42. S. Zhang, Y. Yang, Z. Liang, and et al. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells PloS One 8 2013 e83699
43. R.A. Sharma, S.A. Euden, S.L. Platton, and et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance Clin Cancer Res 10 2004 6847
44. N. Dhillon, B.B. Aggarwal, R.A. Newman, and et al. Phase II trial of curcumin in patients with advanced pancreatic cancer Clin Cancer Res 14 2008 4491
45. A. Goel, A.B. Kunnumakkara, and B.B. Aggarwal Curcumin as "curecumin": from kitchen to clinic Biochem Pharmacol 75 2008 787
46. M. Kanai, Y. Otsuka, K. Otsuka, and et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients Cancer Chemother Pharmacol 71 2013 1521